SCHEMBL731429

SCHEMBL731429

CCOc1c[c]cc(OCC)c1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
GLA P06280 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 3/20 0.39
KDM4E B2RXH2 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TP53 P04637 2/20 0.38
LTA4H P09960 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
ADORA1 P30542 3/20 0.38
ADORA2A P29274 2/20 0.38
HSD17B10 Q99714 1/20 0.38
ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL732633 0.93 KMT2A (0.39) ALDH1A1L3MBTL1GLASMN1; SMN2MAPT
SCHEMBL1501712 0.80 RXRA (0.49) L3MBTL1MAPTKDM4ESSTR5
SCHEMBL1501654 0.78 MRGPRX4 (0.52) SMN1; SMN2NPC1RAB9ATP53SSTR5
SCHEMBL733057 0.78 CA1 (0.44) ALDH1A1SMN1; SMN2MAPTHPGDKDM4E
SCHEMBL16575393 0.77 ADORA3 (0.49) ALDH1A1L3MBTL1GLASMN1; SMN2MAPT
SCHEMBL6525290 0.77 ADRB2 (0.41) ALDH1A1L3MBTL1GLASMN1; SMN2MAPT
SCHEMBL730845 0.76 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KDM4ELMNAGAA
SCHEMBL28451770 0.74 PDE4A (0.41) ALDH1A1L3MBTL1MAPTHPGDKDM4E
SCHEMBL730889 0.74 GRM5 (0.39) ALDH1A1L3MBTL1MAPTHPGDKDM4E
SCHEMBL730813 0.74 PDE4A (0.36) SMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 ALDH1A1 113/4885L3MBTL1 3118/4885GLA 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.